Blog
RSS FeedPosted by Michael Wonder on 04 Oct 2024
Blue Shield of California slashes cost of world's best selling drug
1 October 2024 - Non-profit health plan collaborates with Fresenius Kabi and Evio Pharmacy Solutions to purchase FDA approved Humira biosimilar ...
Posted by Michael Wonder on 08 Oct 2024
New cheaper medicines for auto-immune conditions, cancer and heart disease
8 October 2024 - Australians with types of vasculitis, leukaemia, heart disease, ulcerative colitis and arthritis now have access to ...
Posted by Michael Wonder on 08 Oct 2024
Updated information about PHARMAC's priority lists
8 October 2024 - PHARMAC’s quarterly Pūahoaho Report provides the latest information about applications for medicines, vaccines, and related products that ...
Posted by Michael Wonder on 08 Oct 2024
Neuvivo seeks FDA approval for its breakthrough ALS treatment NP001
7 October 2024 - Neuvivo today announced it submitted a new drug application to the US FDA for NP001 (sodium chlorite ...
Posted by Michael Wonder on 07 Oct 2024
Ultragenyx receives breakthrough therapy designation for setrusumab (UX143) in osteogenesis imperfecta
7 October 2024 - Ultragenyx today announced that it has received breakthrough therapy designation from the US FDA for setrusumab (UX143) ...
Posted by Michael Wonder on 07 Oct 2024
Crossing the equity chasm: addressing a second valley of death in biomedical innovation
3 October 2024 - Traditionally, the term valley of death refers to the gap where advancements in basic research fail to ...
Posted by Michael Wonder on 07 Oct 2024
New flexible service through our scientific advice program
26 September 2024 - Drug sponsors can now request a flexible service through our scientific advice program that can include ...
Posted by Michael Wonder on 07 Oct 2024
Confirmatory trials of accelerated approval drugs — will imposing fines reduce delays?
5 October 2024 - In 1992, patient advocacy groups convinced the FDA to develop an accelerated approval program, which allowed new ...
Posted by Michael Wonder on 07 Oct 2024
World first cancer treatment now accessible for hundreds more Aussies as prices slashed with addition to the PBS
4 October 2024 - A world-first cancer treatment, discovered in Melbourne, has been added to the PBS. ...
Posted by Michael Wonder on 07 Oct 2024
Health Canada approves label expansion for Telix’s Illuccix to include patient selection for PSMA targeted therapy
4 October 2024 - Telix Pharmaceuticals today announces that Health Canada has approved the use of Illuccix (kit for the ...
Posted by Michael Wonder on 04 Oct 2024
Consultation on NHS England proposals for a phased launch of obesity injection
3 October 2024 - Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation ...
Posted by Michael Wonder on 04 Oct 2024
Medicines regulators weigh hope and hype with new Alzheimer’s drugs
30 September 2024 - Swiss medicines regulator Swissmedic is expected to decide by the end of the year whether to approve ...
Posted by Michael Wonder on 04 Oct 2024
Enhertu supplemental new drug application submitted in Japan for patients with HER2 low or HER2 ultra-low metastatic breast cancer
4 October 2024 - Submission based on DESTINY-Breast06 phase 3 trial results that showed Enhertu demonstrated a statistically significant and ...
Posted by Michael Wonder on 04 Oct 2024
HHS releases final guidance for second cycle of historic Medicare drug price negotiation program
2 October 2024 - As part of the continued implementation of the Biden-Harris Administration’s historic prescription drug law, the Inflation Reduction ...
Posted by Michael Wonder on 04 Oct 2024
Netarsudil mesylate with latanoprost for the treatment of patients with primary open-angle glaucoma or ocular hypertension
2 October 2024 - NiCE has published final evidence-based recommendations on the use of netarsudil mesylate with latanoprost (Roclanda) for ...